ArticleCureus2025
Very-Low-Dose Clozapine as Maintenance Treatment for Psychosis in a Patient With Dementia With Lewy Bodies: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dementia with Lewy bodies (DLB) is a neurodegenerative disorder characterized by cognitive decline, motor symptoms, and other neuropsychiatric manifestations, including visual hallucinations, delusions and disorganized thought processes that can configure a psychotic episode. Managing psychosis in DLB is challenging due to hypersensitivity to antipsychotics. This case report describes a 72-year-old female patient with DLB who presented with psychosis and Parkinsonian symptoms. Initial management with olanzapine (10 mg) was effective for psychosis but led to motor worsening. The inclusion of levodopa-carbidopa and reduction of olanzapine were not effective in the resolution of symptoms. Transition to clozapine performed and resulted in stabilization of psychotic symptoms and motor symptoms improvement. Initially, the patient presented with severe symptomatic hypotension, that required the tapering off to a very low dose (6.25mg) without severe adverse effects. This report highlights the utility of very-low dose clozapine in managing psychosis in DLB and discusses therapeutic challenges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.